Clinical trial
A Prospective, Multi-center, Randomized, Double-blinded, Placebo-controlled, Parallel, Phase 2 Trial to Evaluate the Efficacy, Safety of PN-101(Mitochondria Isolated From Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells) Single Dose in Patients With Refractory Polymyositis or Dermatomyositis
NCT07122648 is registered in ClinicalTrials.gov with Paean Biotechnology Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multi-center, Randomized, Double-blinded, Placebo-controlled, Parallel, Phase 2 Trial to Evaluate the Efficacy, Safety of PN-101(Mitochondria Isolated From Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells) Single Dose in Patients With Refractory Polymyositis or Dermatomyositis
- Lead sponsor
- Paean Biotechnology Inc.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 31, 2025
- Completion date
- April 30, 2027
- Enrollment
- 36 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.